Genprex, Inc. (GNPX) - Long-Term Debt to Capital

Genprex, Inc. is developing gene therapies for diabetes and oncology, minimizing regulatory risks through diversification. The proprietary OncoPrex system enhances the efficacy of chemotherapy. The long-term debt-to-equity ratio displayed on GURU.Markets stands at 0.00, which characterizes this parameter. R&D efficiency is driven by the robotization of synthesis and sequencing, replacing the manual labor of scientists.

Investors must determine the foundation of a business's financial stability during scaling. This ratio is calculated as the proportion of liabilities with a maturity of more than one year to total equity. By analyzing the long-term debt structure relative to equity, one can assess the company's degree of dependence on borrowed funds. For Genprex, Inc. (GNPX), this balance is critical when implementing costly ESG standards and greening biotechnological developments. Debt optimization ensures the security of ethical research without the risk of losing solvency.